SP1 and non-small cell lung carcinoma: In this study, piperlongumine, by targeting the Sp1/c-Met axis, is expected to overcome the resistance of NSCLC to osimertinib, and the combination of piperlongumine and osimertinib can enhance the sensitivity of NSCLC cells to osimertinib in vivo and vitro.